Literature DB >> 3011664

Specific measurement of angiotensin metabolites and in vitro generated angiotensin II in plasma.

J Nussberger, D B Brunner, B Waeber, H R Brunner.   

Abstract

Combining high-performance liquid chromatography with radioimmunoassay enabled the precise measurement of different angiotensins and their metabolites in plasma. Peptides were extracted from 2 ml of plasma by reversible adsorption to phenylsilyl-silica, separated by isocratic high-performance liquid chromatography, and quantitated by radioimmunoassay using a sensitive but suitably cross-reacting angiotensin II antiserum. For the C-terminal angiotensin II metabolites (2-8)heptapeptide, (3-8)hexapeptide, and (4-8)pentapeptide, overall recoveries of 10 fmol peptide added to 1 ml of plasma were (mean +/- SD), 74 +/- 6, 68 +/- 8, and 67 +/- 11%, respectively. The detection limit for these peptides in plasma was 0.2 fmol/ml. Blanks were below the detection limits. In eight seated normal subjects treated for 4 days with enalapril, 20 mg p.o., q.d., angiotensin II metabolites tended to decrease during the 4 postdrug hours. However, their cumulated concentration in relation to octapeptide increased from 54 to 163% on Day 1 and from 62 to 103% on Day 4. After 4 hours of converting enzyme inhibition with enalapril there was still a close correlation between plasma renin activity and angiotensin-(1-8)octapeptide level (r = 0.83, p less than 0.05) and between blood angiotensin I and angiotensin-(1-8)octapeptide levels (r = 0.86, p less than 0.01). Adding angiotensin I in vitro raised the angiotensin-(1-8)octapeptide levels after incubation at 4 degrees C for 4 hours. Thus, immunoreactive "angiotensin II" does not disappear after converting enzyme inhibition largely because of the cumulated contribution of cross-reacting metabolites and partly because of in vitro generation of true angiotensin II.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3011664     DOI: 10.1161/01.hyp.8.6.476

Source DB:  PubMed          Journal:  Hypertension        ISSN: 0194-911X            Impact factor:   10.190


  19 in total

1.  Vasoconstriction is determined by interstitial rather than circulating angiotensin II.

Authors:  Martin P Schuijt; René de Vries; Pramod R Saxena; Maarten A D H Schalekamp; A H Jan Danser
Journal:  Br J Pharmacol       Date:  2002-01       Impact factor: 8.739

2.  Intraneuronal angiotensinergic system in rat and human dorsal root ganglia.

Authors:  Jaspal Patil; Alexander Schwab; Juerg Nussberger; Thomas Schaffner; Juan M Saavedra; Hans Imboden
Journal:  Regul Pept       Date:  2010-03-24

3.  Does the addition of losartan improve the beneficial effects of ACE inhibitors in patients with anterior myocardial infarction? A pilot study.

Authors:  P Di Pasquale; V Bucca; S Scalzo; S Cannizzaro; A Giubilato; S Paterna
Journal:  Heart       Date:  1999-06       Impact factor: 5.994

4.  Resetting of renal tissular renin-angiotensin and bradykinin-kallikrein systems after unilateral kidney denervation in rats.

Authors:  Jürgen M Bohlender; Jürg Nussberger; Frédéric Birkhäuser; Eric Grouzmann; George N Thalmann; Hans Imboden
Journal:  Histochem Cell Biol       Date:  2017-02-20       Impact factor: 4.304

Review 5.  Angiotensin-converting enzyme inhibitors. Relationship between pharmacodynamics and pharmacokinetics.

Authors:  G G Belz; W Kirch; C H Kleinbloesem
Journal:  Clin Pharmacokinet       Date:  1988-11       Impact factor: 6.447

6.  Cellular localization and regional distribution of an angiotensin II-forming chymase in the heart.

Authors:  H Urata; K D Boehm; A Philip; A Kinoshita; J Gabrovsek; F M Bumpus; A Husain
Journal:  J Clin Invest       Date:  1993-04       Impact factor: 14.808

7.  Assessment of the role of the renin-angiotensin system in cardiac contractility utilizing the renin inhibitor remikiren.

Authors:  J P van Kats; L M Sassen; A H Danser; M P Polak; L K Soei; F H Derkx; M A Schalekamp; P D Verdouw
Journal:  Br J Pharmacol       Date:  1996-03       Impact factor: 8.739

8.  Endogenous angiotensinergic system in neurons of rat and human trigeminal ganglia.

Authors:  Hans Imboden; Jaspal Patil; Juerg Nussberger; Françoise Nicoud; Benno Hess; Nermin Ahmed; Thomas Schaffner; Maren Wellner; Dominik Müller; Tadashi Inagami; Takaaki Senbonmatsu; Jaroslav Pavel; Juan M Saavedra
Journal:  Regul Pept       Date:  2009-02-12

9.  Haemodynamic and hormonal effects of cilazapril in comparison with propranolol in healthy subjects and in hypertensive patients.

Authors:  C H Kleinbloesem; K Erb; J Essig; K Breithaupt; G G Belz
Journal:  Br J Clin Pharmacol       Date:  1989       Impact factor: 4.335

10.  Correlation between plasma concentration of cilazapril and haemodynamic and hormonal effects in healthy man.

Authors:  M Burnier; V Mooser; J Nussberger; B Waeber; H R Brunner
Journal:  Br J Clin Pharmacol       Date:  1989       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.